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Abstract
The adrenal chromaffin cells synthesize and release cate-
cholamine (mostly epinephrine and norepinephrine) and dif-
ferent peptides, such as the neuropeptide Y (NPY). NPY
stimulates catecholamine release through NPY Y1 receptor in
mouse chromaffin cells. The aim of our study was to deter-
mine the intracellular signaling events coupled to NPY Y1
receptor activation that lead to stimulation of catecholamine
release from mouse chromaffin cells. The stimulatory effect of
NPY mediated by NPY Y1 receptor activation was lost in the
absence of extracellular Ca2+. On the other hand, inhibition of
nitric oxide synthase and guanylyl cyclase also decreased the
stimulatory effect of NPY. Moreover, catecholamine release
stimulated by NPY or by the nitric oxide donor (NOC-18) was
inhibited by mitogen-activated protein kinase (MAPK) and
protein kinase C inhibitors. In summary, in mouse chromaffin
cells, NPY evokes catecholamine release by the activation the
NPY Y1 receptor, in a Ca
2+-dependent manner, by activating
mitogen-activated protein kinase and promoting nitric oxide
production, which in turn regulates protein kinase C and
guanylyl cyclase activation.
Keywords: adrenal mouse chromaffin cells, catecholamine
release, mitogen-activated protein kinase, neuropeptide Y,
nitric oxide, NPY Y1 receptor.
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Chromaffin cells are neuroendocrine cells specialized for
synthesis, storage and release of catecholamine [mainly
epinephrine (EP) and norepinephrine (NE)]. Neuropeptide Y
(NPY) is a 36-aminoacid peptide co-stored and co-released
with catecholamine, which also has a modulatory effect on
the secretory activity of chromaffin cells (Cavadas et al.
2001, 2006). There are six NPY receptors coupled to G-
proteins: NPY Y1, Y2, Y3, Y4, Y5, and y6 receptors (Michel
1991; Krause et al. 1992; Silva et al. 2002). Recently, we
have demonstrated that mouse adrenal glands contain mRNA
for Y1, Y2, and Y5 NPY receptors (Cavadas et al. 2006).
Moreover, NPY stimulates catecholamine release from
chromaffin cells isolated from adrenal glands of wild-type
mice, but not in chromaffin cells of NPY Y1 knockout mice
(Cavadas et al. 2006). The NPY Y1 receptor is coupled to a
variety of second messenger systems, including the increase
of intracellular [Ca2+], and the inhibition of adenylate-
cyclase, resulting in a decrease of protein kinase A (PKA)
activity (Mihara et al. 1989; Aakerlund et al. 1990; Stros-
berg 1991; Herzog et al. 1992; Cavadas et al. 2001; Silva
et al. 2002). Other intracellular mechanisms coupled to this
receptor have been described. Some studies show that the
activation of NPY Y1 receptor stimulates phospholipase C
that will induce an increase both in inositol 1,4,5 triphos-
phate production, mobilizing Ca2+ from intracellular stores,
and in diacylglycerol production, the endogenous activator of
protein kinase C (PKC) (Daniels et al. 1989; Michel et al.
1992; Nishizuka 1992; Misra et al. 2004; Heredia Mdel et al.
2005). Moreover, in transfected Chinese Hamster Ovary cells,
it was demonstrated that NPY Y1 receptor is coupled to
mitogen-activated protein kinases (MAPKs) phosphorylation
involving different kinases such as PKC, Ras, PI3K, and Akt
(Nakamura et al. 1995; Mannon and Raymond 1998; Nie and
Selbie 1998; Mannon and Mele 2000).
Intracellular mechanisms coupled to NPY Y1 receptor that
stimulate catecholamine release from mouse chromaffin were
not yet investigated. Several intracellular mechanisms
involved in the stimulation of catecholamine secretion in
chromaffin cells are already known. The Ca2+ entry through
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voltage-operated channels of the plasma membrane is essen-
tial for triggering the secretory response (Douglas 1968;
Smith et al. 1998). Protein kinases, such as MAPK and PKC,
also participate in the regulation of secretion in chromaffin
cells (Sena et al. 1995; Cox et al. 1996; Cox and Parsons
1997; Smith et al. 1998; Teschemacher and Seward 2000).
Nitric oxide (NO) is synthesized from L-arginine by the
enzyme NO synthase (NOS), which is reported to exist in
three major isoenzymatic forms: neuronal NOS (nNOS),
endothelial NOS, and inducible NOS. In chromaffin cells
from adrenal medulla, the presence of nNOS was already
demonstrated by several techniques (Oset-Gasque et al. 1994,
1998; Schwarz et al. 1998). Moreover, using imunohisto-
chemical methods, NOS-containing fibers closely associated
with chromaffin cells were observed (Afework et al. 1994;
Heym et al. 1994; Tanaka et al. 1996). Of the three isoforms
of NOS, nNOS has received the most attention as a potential
modulator of catecholamine secretion. However there are
some contradictory reports concerning the role of NO on basal
and evoked catecholamine secretion in chromaffin cells (Oset-
Gasque et al. 1994, 1998; Torres et al. 1994; Schwarz et al.
1998; Vicente et al. 2002; McNeill and Perry 2005). Recently,
it was shown, in other systems, that NPY induces NO
production, suggesting that NO is a potential mediator of NPY
function (Dimitrijevic et al. 2006).
The aim of the present study was to investigate the
signaling pathways involved in catecholamine release stim-
ulated by NPY Y1 receptor activation, including the role of
NO, in mouse chromaffin cells.
Materials and methods
Materials
Neuropeptide Y was purchased from Novabiochem (Laufelfingen,
Switzerland); MAPK inhibitor (PD 98059) was from RBI (Natick,
MA, USA); H89 (PKA inhibitor), bisindolylmaleimide I (PKC
inhibitor), forskolin, phorbol 12–myristate 13 acetate (PMA), L-
NAME (L-nitroarginine-methyl-ester; NOS inhibitor), collagenase
solution (Type H), penicillin, streptomycin were obtained from
Sigma Chemical Co. (St Louis, MO, USA); ODQ (1H-[1,2,4]ox-
adiazolo-[4,3-a]quinoxalin-1-one; guanylate cyclase inhibitor) was
from Tocris (Bristol, UK); NOC-18 was from Alexis Corporation
(Lausanne, Switzerland), Dulbecco’s Modified Eagle’s Medium/
Ham’s F12 was purchased from Invitrogen (Eugene, Oregon, USA)
and fetal calf serum from Biochrom (Berlin, Germany).
Primary cultures of mouse chromaffin cells
Cultures of mouse chromaffin cells were prepared as previously
described (Rosmaninho-Salgado et al. 2007). Adrenal glands were
obtained from 10 to 12 weeks old mice. Mice were sacrificed and the
adrenal glands rapidly removed, cut into small pieces, and digested
during 30 min at 37ºC in a 0.2% collagenase solution in Hanks
Balanced Salt Solution with 100 UI/mL penicillin and 100 lg/mL
streptomycin. The digested tissue was washed twice by resuspension
in the culture medium: Dulbecco’s Modified Eagle’s Medium/Ham’s
F12, 10% fetal calf serum, 100 UI/mL penicillin, and 100 lg/mL
streptomycin. Cells were maintained during 3–5 days at 37C with
95% O2 and 5% CO2.
Release experiments
The release experiments were performed as previously described
(Rosmaninho-Salgado et al. 2007). Cells were plated on 48 multi-well
plates (100 000 chromaffin cells/well) and release experiments were
performed 3 days after plating. Culture medium was aspirated and
cells washed three times in Krebs buffer (111 mmol/L NaCl,
2.5 mmol/L CaCl2, 4.7 mmol/L KCl, 1.2 mmol/L MgSO4,
1.2 mmol/L KH2PO4, 24.8 mmol/L NaHCO3, 11.1 mmol/L glucose,
and 15 mmol/L HEPES, pH 7.4). To study the effects of drugs on
catecholamine release, cells were incubated for 10 min with Krebs
buffer (basal release) with or without drugs. To evaluate the role of
extracellular Ca2+, cells were incubated during 10 min with Krebs
buffer (basal release) or in a Ca2+-free Krebs buffer (111 mmol/L
NaCl, 0.38 mmol/L CaCl2, 0.5 mmol/L EGTA, 4.7 mmol/L KCl,
1.2 mmol/L MgSO4, 1.2 mmol/L KH2PO4, 24.8 mmol/L NaHCO3,
11.1 mmol/L glucose, and 15 mmol/LHEPES, pH 7.4) in the presence
or absence of NPY (100 nmol/L). Samples were acidified with HClO4
(0.4 mmol/L) and catecholamine were extracted on alumina and
quantified by HPLC with electrochemical detection (ESA, Coulochem
II, Chelmsford, MA, USA) (Cavadas et al. 2001). The release of
catecholamine and NPY was expressed as the percentage of
intracellular content and the effect of drugs in each experiment
expressed as the percentage of change relatively to the basal release.
Drugs used: NPY; NPY Y1 receptor antagonist, BIBP 3226; MAPK
inhibitor, PD 98059; PKA inhibitor, H89, PKC inhibitor, bis-
indolylmaleimide I; NOS inhibitor, L-NAME; inactive L-NAME
stereoisomer, D-NAME; guanylyl cyclase (GC) inhibitor, ODQ; NO
donor, NOC-18; PKA stimulator, forskolin; PKC stimulator, PMA.
Statistical analysis
The data were analyzed using a two-factor ANOVA tests. Data
expressed as mean ± SEM.
Results
Neuropeptide Y stimulates catecholamine release via
NPY Y1 receptors in a Ca
2+-dependent manner
When mouse chromaffin cells were incubated with NPY
(100 nmol/L) we observed an increase of catecholamine
release: 243.4 ± 13.9% and 228.9 ± 15.7% of NE and EP
release, respectively, compared to basal release (Fig. 1). The
NPYY1 receptor antagonist, BIBP 3226 (1 lmol/L), inhibited
thisNPY stimulatory effect. The release of catecholamine from
chromaffin cells induced by NPYwas completely abolished in
the Ca2+-free Krebs buffer (Fig. 1). The absence of Ca2+ did
not alter the basal catecholamine release (data not shown).
Protein kinase C and mitogen-activated protein kinase,
but not protein kinase A, mediate neuropeptide
Y-stimulated catecholamine release
To investigate which signaling pathways are involved in
catecholamine release stimulated by NPY Y1 receptor, we
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tested PKA, PKC, and MAPK inhibitors (Fig. 2). The
MAPK inhibitor (PD 98059, 50 lmol/L) reduced 64.7 ±
17.9% and 59.1 ± 8.5% the stimulatory effect of NPYon NE
and EP release, respectively. The PKC inhibitor also
inhibited the stimulatory effect of NPY: 100.0 ± 4.6% and
71.0 ± 15.9% inhibition of the stimulatory effect of NPY on
NE and EP release, respectively. In contrast, the PKA
inhibitor did not change catecholamine release evoked by
NPY (Fig. 2).
The NO-cGMP pathway mediates neuropeptide
Y-stimulated catecholamine release in a protein kinase
C-dependent manner
The role of NO on catecholamine release stimulated by NPY
was studied by using a specific NOS inhibitor (L-NAME,
500 lmol/L). L-NAME inhibited 40.5 ± 14.9% and
42.3 ± 20.3% the stimulatory effect of NPY on NE and EP
release, respectively (Fig. 3). D-NAME (500 lmol/L), an
inactive stereoisomer of L-NAME, did not change catechol-
amine release evoked by NPY (data not shown). The direct
effect of NO on catecholamine release was investigated by
incubating the cells with an exogenous NO donor (NOC-18,
100 lmol/L). This NO donor increased up to 255.3 ± 17.5%
and 251.1 ± 21.1% the NE and EP release compared to basal
release (Fig. 3). Moreover, the GC inhibitor (ODQ, 50 lmol/
L) significantly decreased the NPY and NOC-18 stimulatory
effect on catecholamine release (Fig. 3). The percentage of
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Fig. 1 NPY induces catecholamine release through NPY Y1 receptor
in a Ca2+-dependent manner in mouse chromaffin cells. Cells were
incubated with NPY (100 nmol/L) for 10 min in the presence of the
NPY Y1 antagonist BIBP 3226 (1 lmol/L) or in Ca
2+-free buffer. Cat-
echolamine were measured by HPLC as described in Materials and
methods. Data expressed as percentage of basal release; mean ±
SEM; three to eight independent cultures of mice chromaffin cells;
each condition was performed in triplicate. ***p < 0.001 compared to
basal release; +++p < 0.001 compared to NPY (100 nmol/L). Two-way
ANOVA post hoc test was used as statistical test.
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Fig. 2 Signal transduction pathways involved in catecholamine
release stimulated by NPY in mouse chromaffin cells. Cells were
incubated for 10 min with NPY (100 nmol/L) alone or with MAPK
inhibitor (PD 98059, 50 lmol/L), PKA inhibitor (H89, 1 lmol/L), or PKC
inhibitor (bisindolylmaleimide I, 1 lmol/L). Catecholamine were
measured by HPLC as described in Materials and methods. Data
expressed as percentage of basal release; mean ± SEM; three to
eight different mice chromaffin cells culture; each condition was
performed in triplicate. **p < 0.01 and ***p < 0.001 compared to
basal release; +++p < 0.001 compared to NPY (100 nmol/L). Two-way
ANOVA post hoc test was used as statistical test.
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Fig. 3 Role of NO and cyclic GMP on catecholamine release stimu-
lated by NPY. Cells were pre-incubated for 15 min with a NOS inhibitor
(L-NAME, 500 lmol/L) or a GC inhibitor (ODQ, 50 lmol/L), followed by
the stimulation with NPY (100 nmol/L) for 10 min in the presence of
the inhibitors . Cells were stimulated with an exogenous NO donor
(NOC-18, 100 lmol/L) with or without ODQ (50 lmol/L). Catechola-
mine were measured by HPLC as described in Materials and methods.
Data expressed as percentage of basal release; mean ± SEM, three
to eight different mice chromaffin cells culture; each condition was
performed in triplicate. *p < 0.05, **p < 0.01, and ***p < 0.001 com-
pared to basal release; +p < 0.05, ++p < 0.01, and +++p < 0.001
compared to NPY (100 nmol/L); ###p < 0.001 compared to NOC-18
(100 lmol/L). Two-way ANOVA post hoc test was used as statistical
test.
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inhibition by ODQ on NPY-evoked release was
37.4 ± 11.5% and 39.8 ± 11.1% (NE and EP, respectively).
ODQ also inhibited the stimulatory effect of NOC-18:
63.3 ± 6.7% and 59.7 ± 10.7% inhibition of NE and EP
release evoked by NOC-18, respectively. L-NAME or ODQ
alone did not change non-stimulated catecholamine release
(data not shown).
Subsequently, we studied the involvement of MAPK,
PKA, and PKC on catecholamine release evoked by NO.
MAPK or PKA inhibitors did not change the NOC-18
stimulatory effect (Fig. 4). However, the PKC inhibitor
decreased the stimulatory effect of NOC-18 on NE and EP
release (Fig. 4). The PKC stimulator, PMA (200 nmol/L),
induced an increase up to 219.1 ± 18.6% and 209.8 ± 13.2%
the NE and EP release compared to basal release, and this
stimulatory effect was not changed by the presence of
L-NAME (Fig. 4).
Discussion
NPY Y1 receptor mediates the effect of neuropeptide
Y on catecholamine release in mouse chromaffin cells
In the present study, we observed that the NPY Y1
antagonist, BIBP 3226, inhibited the NPY stimulatory effect
on catecholamine release from mouse adrenal chromaffin
cells. This result is in agreement with a previous study from
our group (Cavadas et al. 2006), showing that NPY
stimulates catecholamine release from chromaffin cells of
wild-type mice, but not in chromaffin cells isolated from
NPY Y1 knockout mice (Cavadas et al. 2006). Together,
these studies show that NPY stimulates catecholamine
release through activation of the NPY Y1 receptor in mouse
chromaffin cells. Moreover, by comparing the activity of the
catecholamine synthesizing enzyme tyrosine hydroxylase
(TH) in the adrenal glands of wild-type and NPY Y1
knockout mice we have shown that NPY Y1 receptor
regulates catecholamine synthesis (Cavadas et al. 2006). The
interaction between NPY Y1 and TH was confirmed using Y1
expressing cells transfected with the TH promoter, and it was
shown that NPY acts by a PKA pathway which activates the
cAMP response element-binding elements promoting the
cAMP response element site phosphorylation and, conse-
quently, the induction of TH transcription (Cavadas et al.
2006). As catecholamine synthesis and release are coupled,
these studies suggest a role forNPYY1 receptor in intracellular
catecholamine homeostasis in mouse adrenal gland.
Other studies, using bovine chromaffin cells, demonstrate
that NPY regulates catecholamine homeostasis in a different
manner. In fact, in these cells, NPY was reported to have an
inhibitory effect on catecholamine secretion and to decrease
TH activity (Zheng et al. 1997). On the other hand, also in
bovine chromaffin cells, NPY inhibits PKA activity,
subsequent to adenylate cyclase inhibition and decreases
cAMP production (Zhu et al. 1992).
Differential protein kinase dependency of neuropeptide
Y-stimulated catecholamine release
Another aim of the present study was to investigate the
signaling pathways coupled to NPY Y1 receptor activation
that evoke catecholamine release from mouse chromaffin
cells. It is well established that Ca2+ entry through voltage-
operated Ca2+ channels of the plasma membrane is essential
for triggering the chromaffin secretory response (Garcia et al.
2006) For example, leptin, angiotensin II, and histamine
activate different types of voltage-sensitive Ca2+ channels
with a consequent increase of catecholamine release from
chromaffin cells (O’Farrell and Marley 1999; Takekoshi
et al. 2001; Cavadas et al. 2003). In the present work, we
also observed that the removal of extracellular Ca2+
decreased the stimulatory effect of NPY through NPY Y1
receptor activation. Although we did not further investigated
the coupling of the NPY Y1 receptor and the increase in
intracellular [Ca2+] in these cells, there are several studies
showing that in other cells types the activation of Y1 receptor
increases intracellular [Ca2+] (Mihara et al. 1989; Aakerlund
et al. 1990; Daniels et al. 1992; van Biesen et al. 1996;
Vanderheyden et al. 1998; Cavadas et al. 2001). Besides its
role on catecholamine release, the increase of intracellular
[Ca2+] may regulates catecholamine synthesis, acting on
Calmodulin-Dependent Protein Kinase II, which phospho-
rylates TH on Ser19 residue (Toska et al. 2002).
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Fig. 4 Intracellular pathways involved on catecholamine release
stimulated by NO. Cells were incubated 10 min with NOC-18
(100 lmol/L) alone or with the MAPK inhibitor (PD 98059, 50 lmol/L),
or the PKA inhibitor (H89, 1 lmol/L) or the PKC inhibitor (bis-
indolylmaleimide I, 1 lmol/L). Cells were incubated with the phorbol
ester (PMA, 200 nmol/L) with or without L-NAME (500 lmol/L) during
10 min. Catecholamine were measured by HPLC as described in
Materials and methods. Data expressed as percentage of basal
release; mean ± SEM, two to eight different mice chromaffin cells
culture; each condition was performed in triplicate. **p < 0.01 and
***p < 0.001 compared to basal release; +p < 0.05 compared to NOC-
18 (100 lmol/L). Two-way ANOVA post hoc test was used as statistical
test.
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Based on the knowledge of the pathways coupled to the
NPY Y1 receptor in other systems, in the present study we
investigated the effect of different kinases inhibitors on
catecholamine release. Our results demonstrate that NPY
stimulated catecholamine release in mouse chromaffin cells
by a MAPK- and a PKC-dependent pathway. However, there
was no significant inhibition of NPY stimulatory effect by
the PKA inhibitor, suggesting that PKA is not involved in
NPY-evoked catecholamine release.
Although NPY Y1 receptor activation causes the inhibition
of adenylate cyclase (Aakerlund et al. 1990; Michel 1991), it
was described that NPY, per se, has no effect on cAMP
accumulation (Prieto et al. 1997). In fact, in human and
bovine chromaffin cells, NPY only inhibited cAMP accu-
mulation stimulated by forskolin, having no effect on non-
stimulated cells (Zheng et al. 2000; Cavadas et al. 2001).
These observations might explain why in our experimental
conditions, with non-stimulated adenylate cyclase, the PKA
inhibitor did not change catecholamine release induced by
NPY.
The coupling of NPY Y1 receptor to MAPK activation
was also demonstrated by others in different cell types
(Mannon and Raymond 1998; Nie and Selbie 1998; Keffel
et al. 1999; Hansel et al. 2001; Chan et al. 2005). More-
over, MAPK activation is involved in catecholamine
synthesis and has been implicated in the secretory response
of adrenal chromaffin cells (Ely et al. 1990; Cox and
Parsons 1997). In fact, in bovine chromaffin cells, the
MAPK inhibitor partially inhibited nicotine- and KCl-
induced catecholamine release (Cox and Parsons 1997).
These studies are in agreement with the present work,
where we observed a role of MAPK on catecholamine
release by NPY Y1 receptor activation in mouse chromaffin
cells.
The present study demonstrates, for the first time, that
NPY Y1 receptor modulates catecholamine release by a
PKC-dependent pathway in mouse chromaffin cells. It has
been shown that NPY Y1 receptor activates PKC in different
cell types, including mouse macrophages, Y1-receptor trans-
fected CHO cells, and rat postnatal neuronal precursor cells
(De la Fuente et al. 1993; Selbie et al. 1995; Hansel et al.
2001). Although some contradiction was found in the
literature regarding the involvement of PKC in promoting
secretory responses in chromaffin cells, NPY modulates
catecholamine release in rat, bovine, and porcine chromaffin
cells and also in rat pheochromocytoma cells, by a PKC-
dependent pathway promoting an increase of Ca2+ influx and
triggering exocytosis (Malhotra et al. 1989; Sena et al. 1995;
McCullough and Westfall 1996; Tanaka et al. 1996;
Warashina 1997; Takekoshi et al. 2001; Shoji-Kasai et al.
2002). Furthermore, it was shown that activation of PKC
promotes vesicle recruitment to the release-ready state prior
to Ca2+-triggered fusion in chromaffin cells (Kumakura et al.
2004).
Role of nitric oxide in catecholamine release following
activation of NPY Y1 receptors
Additionally, in this work we demonstrate that NO is an
intracellular messenger that links NPY Y1 receptor activation
and PKC. Our results show that the stimulatory effect of
NPY Y1 receptor on catecholamine release is inhibited by
L-NAME and by the GC inhibitor ODQ, suggesting that the
activation of the NOS-GC pathway and the downstream
events are important factors leading to NPY induced-
catecholamine secretion. As NO production is largely Ca2+-
dependent, and NPY can lead to Ca2+ entry by causing the
opening of voltage-dependent Ca2+ channels, as discussed
above, the involvement of NO in NPY-induced catechol-
amine release is very likely to occur. In fact, inhibition of
NOS partially prevented NPY-stimulated catecholamine
release. Furthermore, stimulation of chromaffin cells with a
NO donor (NOC-18) had a similar effect on catecholamine
release to that of NPY. Similarly to what it was observed with
NPY, inhibition of PKC blocked the NOC-18-evoked
catecholamine release. Direct activation of PKC with PMA
caused catecholamine release that was not sensitive to
inhibition of NO production by L-NAME, suggesting that
the NO pathway is an upstream activator of PKC. On the
other hand, inhibition of MAPK did not abolish the effect of
NOC-18 on catecholamine release, therefore suggesting that
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Fig. 5 Scheme representing the intracellular pathways involved in
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the MAPK pathway is independent of the PKC-NO-cGMP
pathway.
The role of NO on PKC activation was also demonstrated
in other systems, namely in heart models, where NO
activates the PKC signaling pathway, being implicated in
the development of cardioprotection (Ping et al. 1999; Liu
et al. 2001). Other studies suggest that NO is a mediator of
the effects of NPY Y1 receptor activation. For instance, in a
rat model of focal ischemia with reperfusion, NPY intra-
cerebroventricular injection increased the number of nNOS
positive neurons, the nNOS activity and the NO production,
whereas these effects were inhibited by the Y1 receptor
antagonist, BIBP 3326 (Chen et al. 2002; Chen and Cheung
2005). Moreover, although NPY is known as a potent
vasoconstrictor of peripheral blood vessels, Nilsson et al.
(2000) show that NPY induces vasodilatation via the NPY
Y1 receptor and this effect is inhibited by the NOS inhibitor
L-NAME. Other studies also describe that NO activates GC,
regulating catecholamine secretion in bovine and rainbow
trout chromaffin cells (Oset-Gasque et al. 1994, 1998; Torres
et al. 1994; Schwarz et al. 1998; Vicente et al. 2002;
McNeill and Perry 2005).
In summary, our data show that in mouse chromaffin cells,
NPY evokes catecholamine release by the activation of the
NPY Y1 receptor, in a Ca
2+-dependent manner, either by
activating MAPK or leading to production of NO, which is
linked to the activation of PKC and GC (Fig. 5). These
intracellular signaling mechanisms are also coupled to other
different receptors/systems. The knowledge of these signal-
ing pathways is relevant in pathophysiological conditions
where occur an increase of NPY release from adrenal gland
and an increase of circulating NPY, such as stress or
hypertensive crises (Castagne et al. 1987; Edvinsson et al.
1991; Wocial et al. 1995; Bernet et al. 1998). The increased
NPY activates NPY receptor that induces further adrenal
catecholamine release that putatively aggravates pathological
conditions related to adrenergic receptor activation.
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